Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 15/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7219458 | 0.93 | CRHR1 (0.35) | CRHR1MAPK1 | |
| SCHEMBL7220766 | 0.93 | CRHR1 (0.39) | CRHR1OPRK1MAPK1 | |
| SCHEMBL7213701 | 0.88 | CRHR1 (0.41) | CRHR1KCNH2 | |
| SCHEMBL7220785 | 0.88 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL7214595 | 0.86 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL7219403 | 0.86 | CRHR1 (0.36) | CRHR1OPRK1MAPK1 | |
| SCHEMBL7219238 | 0.85 | CRHR1 (0.32) | CRHR1MAPK1 | |
| SCHEMBL7219429 | 0.84 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL7220769 | 0.84 | CRHR1 (0.36) | CRHR1OPRK1MAPK1 | |
| SCHEMBL7220787 | 0.81 | CRHR1 (0.34) | CRHR1OPRK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | claimed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | claimed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | claimed |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-01-31 | — | — | US | disclosed |
| US-6294671-B1 | FOR THERAPY OF PSYCHIATRIC DISORDERS AND NEUROLOGICAL DISEASES INCLUDING AFFECTIVE DISORDER, ANXIETY, DEPRESSION, HEADACHE, IRRITABLE BOWEL SYNDROME, POST-TRAUMATIC STRESS DISORDER, SUPRANUCLEAR PALSY, IMMUNE SUPPRESSION, ALZHEIMER'S DISEASE | DUPONT PHARMACEUTICALS COMPANY | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013461-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885KCNH2 2785/4885OPRK1 87/4885 |
| US-20030114451-A1 | Isoxazolo [4,5-d] pyrimidines as CRF antagonists | CRHR1, P2RX5, P2RX1 | CRHR1 1/4885KCNH2 2785/4885OPRK1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.